ID   GSK3B_MOUSE             Reviewed;         420 AA.
AC   Q9WV60;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 2.
DT   22-JUL-2015, entry version 162.
DE   RecName: Full=Glycogen synthase kinase-3 beta;
DE            Short=GSK-3 beta;
DE            EC=2.7.11.26;
DE   AltName: Full=Serine/threonine-protein kinase GSK3B;
DE            EC=2.7.11.1;
GN   Name=Gsk3b;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Testis;
RA   Salameh W.A., Guo T.B., Chan K.C., Mitchell A.P.;
RT   "Testicular expression and hormonal control of glycogen synthase
RT   kinase 3, a homologue of yeast RIM11.";
RL   Submitted (FEB-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=Czech II, and FVB/N; TISSUE=Mammary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=10894547; DOI=10.1038/35017574;
RA   Hoeflich K.P., Luo J., Rubie E.A., Tsao M.S., Jin O., Woodgett J.R.;
RT   "Requirement for glycogen synthase kinase-3beta in cell survival and
RT   NF-kappaB activation.";
RL   Nature 406:86-90(2000).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-389, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic brain;
RX   PubMed=15345747; DOI=10.1074/mcp.M400085-MCP200;
RA   Ballif B.A., Villen J., Beausoleil S.A., Schwartz D., Gygi S.P.;
RT   "Phosphoproteomic analysis of the developing mouse brain.";
RL   Mol. Cell. Proteomics 3:1093-1101(2004).
RN   [5]
RP   INTERACTION WITH ARRB2.
RX   PubMed=16051150; DOI=10.1016/j.cell.2005.05.012;
RA   Beaulieu J.-M., Sotnikova T.D., Marion S., Lefkowitz R.J.,
RA   Gainetdinov R.R., Caron M.G.;
RT   "An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic
RT   neurotransmission and behavior.";
RL   Cell 122:261-273(2005).
RN   [6]
RP   FUNCTION, AND MUTAGENESIS OF SER-9.
RX   PubMed=15791206; DOI=10.1038/sj.emboj.7600633;
RA   McManus E.J., Sakamoto K., Armit L.J., Ronaldson L., Shpiro N.,
RA   Marquez R., Alessi D.R.;
RT   "Role that phosphorylation of GSK3 plays in insulin and Wnt signalling
RT   defined by knockin analysis.";
RL   EMBO J. 24:1571-1583(2005).
RN   [7]
RP   FUNCTION IN MCL1 PHOSPHORYLATION.
RX   PubMed=16543145; DOI=10.1016/j.molcel.2006.02.009;
RA   Maurer U., Charvet C., Wagman A.S., Dejardin E., Green D.R.;
RT   "Glycogen synthase kinase-3 regulates mitochondrial outer membrane
RT   permeabilization and apoptosis by destabilization of MCL-1.";
RL   Mol. Cell 21:749-760(2006).
RN   [8]
RP   FUNCTION IN AXON FORMATION.
RX   PubMed=17391670; DOI=10.1016/j.febslet.2007.03.018;
RA   Garrido J.J., Simon D., Varea O., Wandosell F.;
RT   "GSK3 alpha and GSK3 beta are necessary for axon formation.";
RL   FEBS Lett. 581:1579-1586(2007).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=17242355; DOI=10.1073/pnas.0609836104;
RA   Villen J., Beausoleil S.A., Gerber S.A., Gygi S.P.;
RT   "Large-scale phosphorylation analysis of mouse liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:1488-1493(2007).
RN   [10]
RP   FUNCTION IN REGULATION OF PANCREATIC BETA-CELLS.
RX   PubMed=18288891; DOI=10.1371/journal.pbio.0060037;
RA   Tanabe K., Liu Z., Patel S., Doble B.W., Li L., Cras-Meneur C.,
RA   Martinez S.C., Welling C.M., White M.F., Bernal-Mizrachi E.,
RA   Woodgett J.R., Permutt M.A.;
RT   "Genetic deficiency of glycogen synthase kinase-3beta corrects
RT   diabetes in mouse models of insulin resistance.";
RL   PLoS Biol. 6:E37-E37(2008).
RN   [11]
RP   INTERACTION WITH DISC1.
RX   PubMed=19303846; DOI=10.1016/j.cell.2008.12.044;
RA   Mao Y., Ge X., Frank C.L., Madison J.M., Koehler A.N., Doud M.K.,
RA   Tassa C., Berry E.M., Soda T., Singh K.K., Biechele T.,
RA   Petryshen T.L., Moon R.T., Haggarty S.J., Tsai L.H.;
RT   "Disrupted in schizophrenia 1 regulates neuronal progenitor
RT   proliferation via modulation of GSK3beta/beta-catenin signaling.";
RL   Cell 136:1017-1031(2009).
RN   [12]
RP   INTERACTION WITH AXIN1 AND ZBED3, AND MUTAGENESIS OF LYS-85.
RX   PubMed=19141611; DOI=10.1074/jbc.M807753200;
RA   Chen T., Li M., Ding Y., Zhang L.S., Xi Y., Pan W.J., Tao D.L.,
RA   Wang J.Y., Li L.;
RT   "Identification of zinc-finger BED domain-containing 3 (Zbed3) as a
RT   novel Axin-interacting protein that activates Wnt/beta-catenin
RT   signaling.";
RL   J. Biol. Chem. 284:6683-6689(2009).
RN   [13]
RP   FUNCTION.
RX   PubMed=20123978; DOI=10.1128/MCB.01047-09;
RA   Kurabayashi N., Hirota T., Sakai M., Sanada K., Fukada Y.;
RT   "DYRK1A and glycogen synthase kinase 3beta, a dual-kinase mechanism
RT   directing proteasomal degradation of CRY2 for circadian timekeeping.";
RL   Mol. Cell. Biol. 30:1757-1768(2010).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH ARNTL/BMAL1.
RX   PubMed=20049328; DOI=10.1371/journal.pone.0008561;
RA   Sahar S., Zocchi L., Kinoshita C., Borrelli E., Sassone-Corsi P.;
RT   "Regulation of BMAL1 protein stability and circadian function by
RT   GSK3beta-mediated phosphorylation.";
RL   PLoS ONE 5:E8561-E8561(2010).
RN   [15]
RP   FUNCTION.
RX   PubMed=21295697; DOI=10.1016/j.cell.2010.12.033;
RA   Wu X., Shen Q.T., Oristian D.S., Lu C.P., Zheng Q., Wang H.W.,
RA   Fuchs E.;
RT   "Skin stem cells orchestrate directional migration by regulating
RT   microtubule-ACF7 connections through GSK3beta.";
RL   Cell 144:341-352(2011).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF DPYSL2, PHOSPHORYLATION AT SER-9, AND
RP   MUTAGENESIS OF SER-9.
RX   PubMed=22057101; DOI=10.1038/ncb2373;
RA   Wakatsuki S., Saitoh F., Araki T.;
RT   "ZNRF1 promotes Wallerian degeneration by degrading AKT to induce
RT   GSK3B-dependent CRMP2 phosphorylation.";
RL   Nat. Cell Biol. 13:1415-1423(2011).
RN   [17]
RP   FUNCTION, AND PHOSPHORYLATION AT SER-9.
RX   PubMed=23395175; DOI=10.1016/j.cmet.2012.12.017;
RA   Kaasik K., Kivimae S., Allen J.J., Chalkley R.J., Huang Y., Baer K.,
RA   Kissel H., Burlingame A.L., Shokat K.M., Ptacek L.J., Fu Y.H.;
RT   "Glucose sensor O-GlcNAcylation coordinates with phosphorylation to
RT   regulate circadian clock.";
RL   Cell Metab. 17:291-302(2013).
CC   -!- FUNCTION: Constitutively active protein kinase that acts as a
CC       negative regulator in the hormonal control of glucose homeostasis,
CC       Wnt signaling and regulation of transcription factors and
CC       microtubules, by phosphorylating and inactivating glycogen
CC       synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1,
CC       DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires
CC       primed phosphorylation of the majority of its substrates. In
CC       skeletal muscle, contributes to insulin regulation of glycogen
CC       synthesis by phosphorylating and inhibiting GYS1 activity and
CC       hence glycogen synthesis. May also mediate the development of
CC       insulin resistance by regulating activation of transcription
CC       factors. Regulates protein synthesis by controlling the activity
CC       of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as
CC       glycogen synthase. In Wnt signaling, GSK3B forms a multimeric
CC       complex with APC, AXIN1 and CTNNB1/beta-catenin and phosphorylates
CC       the N-terminus of CTNNB1 leading to its degradation mediated by
CC       ubiquitin/proteasomes. Phosphorylates JUN at sites proximal to its
CC       DNA-binding domain, thereby reducing its affinity for DNA.
CC       Phosphorylates NFATC1/NFATC on conserved serine residues promoting
CC       NFATC1/NFATC nuclear export, shutting off NFATC1/NFATC gene
CC       regulation, and thereby opposing the action of calcineurin.
CC       Phosphorylates MAPT/TAU on 'Thr-548', decreasing significantly
CC       MAPT/TAU ability to bind and stabilize microtubules. Plays an
CC       important role in ERBB2-dependent stabilization of microtubules at
CC       the cell cortex. Phosphorylates MACF1, inhibiting its binding to
CC       microtubules which is critical for its role in bulge stem cell
CC       migration and skin wound repair. Probably regulates NF-kappa-B
CC       (NFKB1) at the transcriptional level and is required for the NF-
CC       kappa-B-mediated anti-apoptotic response to TNF-alpha (TNF/TNFA).
CC       Negatively regulates replication in pancreatic beta-cells,
CC       resulting in apoptosis, loss of beta-cells. Through
CC       phosphorylation of the anti-apoptotic protein MCL1, may control
CC       cell apoptosis in response to growth factors deprivation.
CC       Phosphorylates MUC1 in breast cancer cells, decreasing the
CC       interaction of MUC1 with CTNNB1/beta-catenin. Is necessary for the
CC       establishment of neuronal polarity and axon outgrowth.
CC       Phosphorylates MARK2, leading to inhibit its activity.
CC       Phosphorylates SIK1 at 'Thr-182', leading to sustain its activity.
CC       Phosphorylates ZC3HAV1 which enhances its antiviral activity.
CC       Phosphorylates SFPQ at 'Thr-679' upon T-cell activation.
CC       Phosphorylates SNAI1, leading to its BTRC-triggered ubiquitination
CC       and proteasomal degradation. Phosphorylates NR1D1 st 'Ser-55' and
CC       'Ser-59' and stabilizes it by protecting it from proteasomal
CC       degradation. Regulates the circadian clock via phosphorylation of
CC       the major clock components including ARNTL/BMAL1, CLOCK and PER2.
CC       Phosphorylates CLOCK AT 'Ser-427' and targets it for proteasomal
CC       degradation. Phosphorylates ARNTL/BMAL1 at 'Ser-17' and 'Ser-21'
CC       and primes it for ubiquitination and proteasomal degradation.
CC       Phosphorylates OGT at 'Ser-3' or 'Ser-4' which positively
CC       regulates its activity. {ECO:0000269|PubMed:10894547,
CC       ECO:0000269|PubMed:15791206, ECO:0000269|PubMed:16543145,
CC       ECO:0000269|PubMed:17391670, ECO:0000269|PubMed:18288891,
CC       ECO:0000269|PubMed:20049328, ECO:0000269|PubMed:20123978,
CC       ECO:0000269|PubMed:21295697, ECO:0000269|PubMed:22057101,
CC       ECO:0000269|PubMed:23395175}.
CC   -!- CATALYTIC ACTIVITY: ATP + [tau protein] = ADP + [tau protein]
CC       phosphate.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Activated by phosphorylation at Tyr-216. In
CC       response to insulin, inhibited by phosphorylation at Ser-9 by
CC       PKB/AKT1 and RPS6KA3; phosphorylation at this site causes a
CC       conformational change, preventing access of substrates to the
CC       active site. Inhibited by lithium.
CC   -!- SUBUNIT: Monomer. Interacts with DAB2IP (via C2 domain); the
CC       interaction stimulates GSK3B kinase activation. Interacts (via C2
CC       domain) with PPP2CA (By similarity). Interacts with CABYR, MMP2,
CC       MUC1, NIN and PRUNE (By similarity). Interacts with AXIN1; the
CC       interaction mediates hyperphosphorylation of CTNNB1 leading to its
CC       ubiquitination and destruction. Interacts with and phosphorylates
CC       SNAI1. Interacts with DNM1L (via a C-terminal domain) (By
CC       similarity). Interacts with ARRB2 and DISC1. Found in a complex
CC       composed of MACF1, APC, AXIN1, CTNNB1 and GSK3B (By similarity).
CC       Interacts with SGK3. Interacts with the CLOCK-ARNTL/BMAL1
CC       heterodimer (By similarity). Interacts with AXIN1 and ZBED3.
CC       Interacts with the ARNTL/BMAL1. {ECO:0000250,
CC       ECO:0000269|PubMed:16051150, ECO:0000269|PubMed:19141611,
CC       ECO:0000269|PubMed:19303846, ECO:0000269|PubMed:20049328}.
CC   -!- INTERACTION:
CC       Q02248:Ctnnb1; NbExp=2; IntAct=EBI-400793, EBI-397872;
CC       Q9WUA5:Epm2a; NbExp=2; IntAct=EBI-400793, EBI-1040928;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000250}. Cell membrane {ECO:0000250}. Note=The
CC       phosphorylated form shows localization to cytoplasm and cell
CC       membrane. The MEMO1-RHOA-DIAPH1 signaling pathway controls
CC       localization of the phosphorylated form to the cell membrane (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Phosphorylated by AKT1 and ILK1. Upon insulin-mediated
CC       signaling, the activated PKB/AKT1 protein kinase phosphorylates
CC       and desactivates GSK3B, resulting in the dephosphorylation and
CC       activation of GYS1. Activated by phosphorylation at Tyr-216.
CC       Phosphorylation of Ser-9 in the hippocampus peaks at CT0, whereas
CC       in the liver it peaks at CT12. {ECO:0000269|PubMed:22057101,
CC       ECO:0000269|PubMed:23395175}.
CC   -!- PTM: Mono-ADP-ribosylation by PARP10 negatively regulates kinase
CC       activity. {ECO:0000250}.
CC   -!- DISRUPTION PHENOTYPE: Embryonic lethality at E16 due to hepatocyte
CC       apoptosis. {ECO:0000269|PubMed:10894547}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. GSK-3 subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF156099; AAD39258.2; -; mRNA.
DR   EMBL; BC006936; AAH06936.1; -; mRNA.
DR   EMBL; BC060743; AAH60743.1; -; mRNA.
DR   CCDS; CCDS28163.1; -.
DR   RefSeq; NP_062801.1; NM_019827.6.
DR   UniGene; Mm.394930; -.
DR   PDB; 4NU1; X-ray; 2.50 A; A=1-383.
DR   PDB; 5AIR; X-ray; 2.53 A; A/B=4-420.
DR   PDBsum; 4NU1; -.
DR   PDBsum; 5AIR; -.
DR   ProteinModelPortal; Q9WV60; -.
DR   SMR; Q9WV60; 6-386.
DR   BioGrid; 208115; 27.
DR   IntAct; Q9WV60; 20.
DR   MINT; MINT-4096935; -.
DR   STRING; 10090.ENSMUSP00000023507; -.
DR   BindingDB; Q9WV60; -.
DR   ChEMBL; CHEMBL1075321; -.
DR   PhosphoSite; Q9WV60; -.
DR   MaxQB; Q9WV60; -.
DR   PaxDb; Q9WV60; -.
DR   PRIDE; Q9WV60; -.
DR   Ensembl; ENSMUST00000023507; ENSMUSP00000023507; ENSMUSG00000022812.
DR   GeneID; 56637; -.
DR   KEGG; mmu:56637; -.
DR   UCSC; uc007zen.1; mouse.
DR   CTD; 2932; -.
DR   MGI; MGI:1861437; Gsk3b.
DR   eggNOG; COG0515; -.
DR   GeneTree; ENSGT00520000055635; -.
DR   HOGENOM; HOG000233017; -.
DR   HOVERGEN; HBG014652; -.
DR   InParanoid; Q9WV60; -.
DR   KO; K03083; -.
DR   OrthoDB; EOG7TF78V; -.
DR   PhylomeDB; Q9WV60; -.
DR   TreeFam; TF101104; -.
DR   BRENDA; 2.7.11.26; 3474.
DR   Reactome; REACT_272921; Regulation of HSF1-mediated heat shock response.
DR   Reactome; REACT_274287; Degradation of beta-catenin by the destruction complex.
DR   Reactome; REACT_294625; Ubiquitin-dependent degradation of Cyclin D1.
DR   Reactome; REACT_303008; Beta-catenin phosphorylation cascade.
DR   Reactome; REACT_310780; Degradation of GLI2 by the proteasome.
DR   Reactome; REACT_314392; CRMPs in Sema3A signaling.
DR   Reactome; REACT_317277; disassembly of the destruction complex and recruitment of AXIN to the membrane.
DR   Reactome; REACT_320952; AKT phosphorylates targets in the cytosol.
DR   Reactome; REACT_353777; GLI3 is processed to GLI3R by the proteasome.
DR   ChiTaRS; Gsk3b; mouse.
DR   NextBio; 313081; -.
DR   PMAP-CutDB; Q9WV60; -.
DR   PRO; PR:Q9WV60; -.
DR   Proteomes; UP000000589; Chromosome 16.
DR   Bgee; Q9WV60; -.
DR   CleanEx; MM_GSK3B; -.
DR   ExpressionAtlas; Q9WV60; baseline and differential.
DR   Genevisible; Q9WV60; MM.
DR   GO; GO:0030877; C:beta-catenin destruction complex; IDA:MGI.
DR   GO; GO:0044297; C:cell body; IDA:MGI.
DR   GO; GO:0005813; C:centrosome; ISO:MGI.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:MGI.
DR   GO; GO:0043198; C:dendritic shaft; IDA:MGI.
DR   GO; GO:0030426; C:growth cone; IDA:MGI.
DR   GO; GO:0016020; C:membrane; ISS:UniProtKB.
DR   GO; GO:0043227; C:membrane-bounded organelle; IDA:MGI.
DR   GO; GO:0043025; C:neuronal cell body; IDA:MGI.
DR   GO; GO:0097481; C:neuronal postsynaptic density; IDA:MGI.
DR   GO; GO:0005654; C:nucleoplasm; ISO:MGI.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:MGI.
DR   GO; GO:0016301; F:kinase activity; ISS:UniProtKB.
DR   GO; GO:0051059; F:NF-kappaB binding; ISO:MGI.
DR   GO; GO:0002039; F:p53 binding; ISO:MGI.
DR   GO; GO:0034236; F:protein kinase A catalytic subunit binding; ISO:MGI.
DR   GO; GO:0004672; F:protein kinase activity; IDA:MGI.
DR   GO; GO:0019901; F:protein kinase binding; ISO:MGI.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; ISO:MGI.
DR   GO; GO:0050321; F:tau-protein kinase activity; IDA:MGI.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; ISO:MGI.
DR   GO; GO:0007409; P:axonogenesis; IGI:MGI.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:MGI.
DR   GO; GO:0044337; P:canonical Wnt signaling pathway involved in positive regulation of apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0016477; P:cell migration; IGI:MGI.
DR   GO; GO:0008283; P:cell proliferation; TAS:MGI.
DR   GO; GO:0036016; P:cellular response to interleukin-3; IDA:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; IMP:UniProtKB.
DR   GO; GO:0007010; P:cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; ISS:UniProtKB.
DR   GO; GO:0006983; P:ER overload response; IDA:MGI.
DR   GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IDA:UniProtKB.
DR   GO; GO:0045444; P:fat cell differentiation; IDA:MGI.
DR   GO; GO:0005977; P:glycogen metabolic process; ISO:MGI.
DR   GO; GO:0021766; P:hippocampus development; ISO:MGI.
DR   GO; GO:0044027; P:hypermethylation of CpG island; IMP:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; ISO:MGI.
DR   GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; IDA:CACAO.
DR   GO; GO:0007520; P:myoblast fusion; IDA:MGI.
DR   GO; GO:0014902; P:myotube differentiation; IGI:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:MGI.
DR   GO; GO:0010614; P:negative regulation of cardiac muscle hypertrophy; IDA:MGI.
DR   GO; GO:0014043; P:negative regulation of neuron maturation; IGI:MGI.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IMP:MGI.
DR   GO; GO:0051534; P:negative regulation of NFAT protein import into nucleus; ISS:UniProtKB.
DR   GO; GO:0032091; P:negative regulation of protein binding; ISO:MGI.
DR   GO; GO:0031333; P:negative regulation of protein complex assembly; ISO:MGI.
DR   GO; GO:0009968; P:negative regulation of signal transduction; IEA:UniProtKB-KW.
DR   GO; GO:0009887; P:organ morphogenesis; IMP:MGI.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0016310; P:phosphorylation; IMP:UniProtKB.
DR   GO; GO:0045773; P:positive regulation of axon extension; IGI:MGI.
DR   GO; GO:0001954; P:positive regulation of cell-matrix adhesion; ISO:MGI.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; ISO:MGI.
DR   GO; GO:1901030; P:positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway; IDA:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:MGI.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IDA:MGI.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IGI:MGI.
DR   GO; GO:0032092; P:positive regulation of protein binding; IDA:MGI.
DR   GO; GO:0031334; P:positive regulation of protein complex assembly; ISO:MGI.
DR   GO; GO:0046827; P:positive regulation of protein export from nucleus; ISO:MGI.
DR   GO; GO:2000738; P:positive regulation of stem cell differentiation; IMP:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; ISO:MGI.
DR   GO; GO:0006611; P:protein export from nucleus; IDA:MGI.
DR   GO; GO:0035372; P:protein localization to microtubule; IGI:MGI.
DR   GO; GO:0006468; P:protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0000320; P:re-entry into mitotic cell cycle; IDA:MGI.
DR   GO; GO:0006349; P:regulation of gene expression by genetic imprinting; IMP:BHF-UCL.
DR   GO; GO:0032886; P:regulation of microtubule-based process; IDA:UniProtKB.
DR   GO; GO:0010975; P:regulation of neuron projection development; IGI:MGI.
DR   GO; GO:0071109; P:superior temporal gyrus development; ISO:MGI.
DR   GO; GO:0016055; P:Wnt signaling pathway; IGI:MGI.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR002290; Ser/Thr_dual-sp_kinase.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; ATP-binding; Biological rhythms;
KW   Carbohydrate metabolism; Cell membrane; Complete proteome; Cytoplasm;
KW   Developmental protein; Differentiation; Glycogen metabolism; Kinase;
KW   Membrane; Neurogenesis; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase;
KW   Signal transduction inhibitor; Transferase; Wnt signaling pathway.
FT   CHAIN         1    420       Glycogen synthase kinase-3 beta.
FT                                /FTId=PRO_0000085981.
FT   DOMAIN       56    340       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      62     70       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    181    181       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      85     85       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       9      9       Phosphoserine; by PKB/AKT1, RPS6KA3 and
FT                                SGK3. {ECO:0000269|PubMed:22057101,
FT                                ECO:0000269|PubMed:23395175}.
FT   MOD_RES     216    216       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P49841}.
FT   MOD_RES     389    389       Phosphoserine.
FT                                {ECO:0000269|PubMed:15345747}.
FT   MUTAGEN       9      9       S->A: Loss of phosphorylation; No
FT                                inhibition of activity and constitutively
FT                                active. {ECO:0000269|PubMed:15791206,
FT                                ECO:0000269|PubMed:22057101}.
FT   MUTAGEN      85     85       K->R: Inhibits interaction with AXIN1 and
FT                                ZBED3. {ECO:0000269|PubMed:19141611}.
FT   STRAND       27     29       {ECO:0000244|PDB:5AIR}.
FT   STRAND       38     48       {ECO:0000244|PDB:4NU1}.
FT   STRAND       52     64       {ECO:0000244|PDB:4NU1}.
FT   STRAND       69     75       {ECO:0000244|PDB:4NU1}.
FT   TURN         76     78       {ECO:0000244|PDB:4NU1}.
FT   STRAND       81     88       {ECO:0000244|PDB:4NU1}.
FT   HELIX        97    101       {ECO:0000244|PDB:4NU1}.
FT   STRAND      112    118       {ECO:0000244|PDB:4NU1}.
FT   STRAND      121    124       {ECO:0000244|PDB:5AIR}.
FT   STRAND      127    133       {ECO:0000244|PDB:4NU1}.
FT   HELIX       139    148       {ECO:0000244|PDB:4NU1}.
FT   HELIX       155    173       {ECO:0000244|PDB:4NU1}.
FT   TURN        174    176       {ECO:0000244|PDB:4NU1}.
FT   HELIX       184    186       {ECO:0000244|PDB:4NU1}.
FT   STRAND      187    190       {ECO:0000244|PDB:4NU1}.
FT   TURN        191    194       {ECO:0000244|PDB:4NU1}.
FT   STRAND      195    198       {ECO:0000244|PDB:4NU1}.
FT   HELIX       201    203       {ECO:0000244|PDB:5AIR}.
FT   HELIX       220    222       {ECO:0000244|PDB:5AIR}.
FT   HELIX       225    228       {ECO:0000244|PDB:4NU1}.
FT   HELIX       237    252       {ECO:0000244|PDB:4NU1}.
FT   HELIX       262    273       {ECO:0000244|PDB:4NU1}.
FT   HELIX       278    284       {ECO:0000244|PDB:4NU1}.
FT   HELIX       286    288       {ECO:0000244|PDB:4NU1}.
FT   HELIX       301    304       {ECO:0000244|PDB:4NU1}.
FT   HELIX       311    320       {ECO:0000244|PDB:4NU1}.
FT   HELIX       325    327       {ECO:0000244|PDB:4NU1}.
FT   HELIX       331    335       {ECO:0000244|PDB:4NU1}.
FT   HELIX       338    340       {ECO:0000244|PDB:4NU1}.
FT   HELIX       341    344       {ECO:0000244|PDB:4NU1}.
FT   TURN        364    367       {ECO:0000244|PDB:4NU1}.
FT   HELIX       371    373       {ECO:0000244|PDB:4NU1}.
FT   HELIX       374    377       {ECO:0000244|PDB:4NU1}.
FT   HELIX       380    382       {ECO:0000244|PDB:4NU1}.
SQ   SEQUENCE   420 AA;  46710 MW;  200C3FD1B38B4883 CRC64;
     MSGRPRTTSF AESCKPVQQP SAFGSMKVSR DKDGSKVTTV VATPGQGPDR PQEVSYTDTK
     VIGNGSFGVV YQAKLCDSGE LVAIKKVLQD KRFKNRELQI MRKLDHCNIV RLRYFFYSSG
     EKKDEVYLNL VLDYVPETVY RVARHYSRAK QTLPVIYVKL YMYQLFRSLA YIHSFGICHR
     DIKPQNLLLD PDTAVLKLCD FGSAKQLVRG EPNVSYICSR YYRAPELIFG ATDYTSSIDV
     WSAGCVLAEL LLGQPIFPGD SGVDQLVEII KVLGTPTREQ IREMNPNYTE FKFPQIKAHP
     WTKVFRPRTP PEAIALCSRL LEYTPTARLT PLEACAHSFF DELRDPNVKL PNGRDTPALF
     NFTTQELSSN PPLATILIPP HARIQAAASP PANATAASDT NAGDRGQTNN AASASASNST
//
